Treatment Considerations for CLL

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Treatment Considerations for CLL

Treatment Considerations for CLL

Playback speed

10 seconds

MRD in CLL/SLL: Is It Ready for Prime Time?

By Moffitt Cancer Center FEATURING Jose Sandoval-Sus

287 views

January 25, 2023

0 Comments

Treatment Considerations for CLL

08:57

Carsten Utoft Niemann

Fixed-Duration Therapy in CLL: Is It a Safer Option for Patients?

09:46

Christopher Pleyer

Venetoclax + Obinutuzumab for Previously Untreated CLL: Latest Learn…

19:42

Jacqueline Barrientos

Considerations for Sequencing Treatments in CLL

14:05

The University of Kansas Cancer Center

Five-Year Updates on Venetoclax + Obinutuzumab for Previously Untrea…

Feat. M. Hoffmann

33:21

Moffitt Cancer Center

MRD in CLL/SLL: Is It Ready for Prime Time?

Feat. J. Sandoval-Sus

27:08

Tara Graff

Updates on Venetoclax in CLL

09:45

ASH 2022 Conference Coverage

ASH 2022 Treatment of CLL-Associated Autoimmune Cytopenias and Outco…

Feat. K. Rogers

11:52

ASH 2022 Conference Coverage

ASH 2022 Real-World OS and TTNT by 1L Therapy (BTKi and BCL2i) in Pa…

Feat. W. Archibald, C. Wang

07:24

Kirollos Hanna

MURANO Phase 3 Trial: Enduring Undetectable MRD and Updated Outcomes…

14:12

Northwell Health

Treatment Considerations for Patients With CLL Who Are Elderly or Ha…

Feat. J. Rhodes

14:31

Lydia Scarfò

Upcoming BTKi Therapies in CLL

11:07

SOHO 2022 Tenth Annual Meeting

SOHO 2022: BCL2i in CLL

Feat. A. Chanan-Khan

20:55

ERIC 2022 - European Research Initiative on CLL - ERIC

The Tumor: Biomarker-Guided Treatment in CLL

Feat. O. Al-Sawaf

21:28

ERIC 2022 - European Research Initiative on CLL - ERIC

Combined Inhibition of Signaling and Anti-Apoptotic Pathways in CLL

Feat. P. Hillmen

06:33

Arnon Kater